<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920294</url>
  </required_header>
  <id_info>
    <org_study_id>METC 163023</org_study_id>
    <nct_id>NCT02920294</nct_id>
  </id_info>
  <brief_title>Modulation of Microbial Composition in Ileostomy Patients</brief_title>
  <acronym>INSIDE</acronym>
  <official_title>Modulation of Small Intestinal Microbial Composition and Activity,Systemic Immune Adaptation and Blood Transcriptional Changes Induced by 2-wks Consumption With 2 Fermented Milk Products;a Randomized,Exploratory,Cross-over,Double Blind,Controlled Study in Ileostomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the small intestinal microbiota response in humans to dietary interventions for&#xD;
      two consecutive weeks, and to relate this to parameters of intestinal barrier function and&#xD;
      immune and metabolic responses in blood, as functional outcome parameters of host physiology&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 11, 2017</completion_date>
  <primary_completion_date type="Actual">November 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporal microbial composition and activity in the small intestine in ileal effluent</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Small intestinal permeability by a multi sugar test (urinary recovery of test sugars)</measure>
    <time_frame>2 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene transcription response in blood by transcriptome patterns.</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>Transcriptome patterns will be determined in peripheral blood mononuclear cells obtained from blood samples from the participating ileostoma patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>A panel of biomarkers will be determined in peripheral blood obtained at the start and end of the intervention periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>Peripheral whole blood immune responsiveness towards a subset of bacterial immune-stimuli will be assessed using the standardized truculture system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning urine metabolome profiles</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood metabolome profiles</measure>
    <time_frame>2 weeks intervention</time_frame>
    <description>The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates)</measure>
    <time_frame>2 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acid profiles in ileal effluent</measure>
    <time_frame>2 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Gastrointestinal symptoms by Visual Analogue Scales</measure>
    <time_frame>2 weeks intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and severity of treatment related adverse events</measure>
    <time_frame>2 weeks intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <arm_group>
    <arm_group_label>Probiotic 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 1</intervention_name>
    <description>Fresh fermented dairy drink containing yoghurt ferments</description>
    <arm_group_label>Probiotic 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 2</intervention_name>
    <description>Fresh fermented dairy drink containing probiotic strain</description>
    <arm_group_label>Probiotic 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acidified dairy drink without ferments</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Ileostomy installed at least 3 years prior to participation&#xD;
&#xD;
               -  Free of any complications originating from the colectomy procedure for at least 1&#xD;
                  yr prior to participation, with the exception of possible skin irritation at the&#xD;
                  location of the stoma&#xD;
&#xD;
               -  BMI from 18 till 28 kg/m2&#xD;
&#xD;
               -  Age from 18 till 70 years&#xD;
&#xD;
               -  Available for entire study protocol.&#xD;
&#xD;
               -  For female: If of child bearing potential, female subjects must be using or&#xD;
                  complying with methods of contraception (such as oral birth control pills,&#xD;
                  intra-uterine device, double barrier methods (like condoms and spermicide, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • History of cardiovascular, respiratory, urogenital, hepatic, haematological /&#xD;
             immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue,&#xD;
             musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy,&#xD;
             laboratory assessments which might limit participation in or completion of the study&#xD;
             protocol, and/or major surgery with the exception of total colectomy, hysterectomy&#xD;
             and/or appendectomy.&#xD;
&#xD;
               -  Subject with known lactose intolerance or with known or suspected allergy or&#xD;
                  hypersensitivity to any component of the study product(s) (milk protein for&#xD;
                  example) + sucrose + rhamnose&#xD;
&#xD;
               -  Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the&#xD;
                  principal investigator and the medically responsible MD will judge eligibility to&#xD;
                  participate.&#xD;
&#xD;
               -  Removal of more than 15 cm of the ileum during or at any moment after the&#xD;
                  colectomy procedure&#xD;
&#xD;
               -  Abdominal surgery interfering with gastrointestinal function, upon judgment of&#xD;
                  the principal investigator and the medically responsible MD&#xD;
&#xD;
               -  Use of medication, including proton pump inhibitors, non-steroidal&#xD;
                  anti-inflammatory drugs interfering with endpoints (but except oral&#xD;
                  contraceptives), within 14 days prior to and during participation.&#xD;
&#xD;
               -  Consumption of any probiotic or prebiotic supplements or pre- and probiotics&#xD;
                  containing food products, investigational drugs or participation in any&#xD;
                  scientific intervention study which may interfere with this study (to be decided&#xD;
                  by the principal investigator), in the 4 weeks prior to the study and during&#xD;
                  study participation (E4 PreProbiotics).&#xD;
&#xD;
               -  Use of antibiotics in the 4 weeks prior to the start of study and during study&#xD;
                  participation&#xD;
&#xD;
               -  Prohibited use of pro-, pre- or synbiotics during study period and three months&#xD;
                  prior to start of study. A list with forbidden products will be provided'&#xD;
&#xD;
               -  History of any side effects towards intake of pro- or prebiotic supplements of&#xD;
                  any kind.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Troost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center (MUMC+)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotics, microbiota, ileostoma</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

